Novel drug approvals set to hit a new record in 2018
Amid market volatility, biotech’s best friend comes through once again: the FDA has authorised a bumper 53 new medicines so far in 2018 and several more are expected…
Go or no go? Big decisions for Acelrx, Trevena, Loxo and Astellas
Pain drugs look like they could face different outcomes, while targeted cancer agents will have a big month. Two biosimilar decisions also await.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.